FDA Approves Merck’s CMV Drug

The FDA approved Merck’s Prevymis (letermovir) for prevention of cytomegalovirus infection in adults receiving bone marrow transplants.

The CMV infection occurs in many patients receiving the transplants.

Prevymis earlier was designated a breakthrough therapy and an orphan drug by the FDA.